Article
17 Jan 2025
Year In Review: Top Legal Developments Of 2024
AUTHORS CONTENT
Article
27 Sep 2024
Preliminary Injunction Denied Against Amgen In Aflibercept BPCIA Litigation
Article
16 Aug 2024
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents
Article
16 May 2024
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders
Article
16 Jan 2024
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.
Article
08 Jan 2024
Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed
Article
11 Sep 2023
Formycon Announces FDA Acceptance Of The ABLA For Its Aflibercept Biosimilar
Article
29 May 2023
Amgen Intervenes In Regeneron V. Mylan BPCIA Aflibercept Litigation To Seek Public Access To Sealed Documents
Article
26 May 2023
New Patents Listed In The Purple Book For Regeneron's EYLEA
Article
04 May 2023
Regeneron V. Mylan BPCIA Aflibercept Litigation Update: Claim Construction Order And Stipulation To Narrow The Case For June 2023 Trial
Article
26 Apr 2023
Regeneron V. Mylan – Update On Aflibercept BPCIA Litigation
Article
23 Mar 2023
Aflibercept IPRs Update
Article
13 Jun 2022
FDA Approves Amgen's RIABNI™ (Rituximab-arrx) For Adults With Moderate To Severe Rheumatoid Arthritis
Article
07 Apr 2022
Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institution Of Celltrion PGR
Article
05 Apr 2022
Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar
